A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

498

Participants

Timeline

Start Date

May 26, 2020

Primary Completion Date

September 8, 2021

Study Completion Date

September 8, 2021

Conditions
Knee Osteoarthritis
Interventions
DRUG

Lorecivivint

One intra-articular injection of 0.07 mg lorecivivint in 2 m vehicle

DRUG

Placebo

One intra-articular injection of 0 mg lorecivivint in 2 m vehicle

Trial Locations (76)

10530

Research Site, Hartsdale

14642

Research Site, Rochester

16635

Research Site, Duncansville

20902

Research Site, Wheaton

22911

Research Site, Charlottesville

23219

Research Site, Richmond

27103

Research Site, Winston-Salem

27408

Research Site, Greensboro

28144

Research Site, Salisbury

29406

Research Site, Charleston

29464

Research Site, Mt. Pleasant

29707

Research Site, Fort Mill

30060

Research Site, Marietta

30189

Research Site, Woodstock

30265

Research Site, Newnan

32132

Research Site, Edgewater

32561

Research Site, Gulf Breeze

32789

Research Site 1, Winter Park

33014

Research Site, Miami Lakes

33125

Research Site, Miami

33172

Research Site, Sweetwater

33173

Research Site, Miami

33351

Research Site, Sunrise

33409

Research Site, West Palm Beach

33761

Reserach Site, Clearwater

33880

Research Site, Winter Haven

35205

Research Site, Birmingham

35215

Research Site, Birmingham

36608

Research Site, Mobile

45224

Research Site, Cincinnati

46143

Research Site, Greenwood

46383

Research Site, Valparaiso

47714

Research Site, Evansville

48085

Research Site, Troy

57702

Research Site, Rapid City

60031

Research Site, Gurnee

60523

Research Site, Oak Brook

60607

Research Site, Chicago

63042

Research Site, Hazelwood

63141

Research Site 1, St Louis

Research Site 2, St Louis

64114

Research Site, Kansas City

68114

Research Site, Omaha

70124

Research Site, New Orleans

72205

Research Site, Little Rock

73013

Research Site, Edmond

75007

Research Site, Carrollton

75075

Research Site, Plano

75231

Research Site, Dallas

77029

Research Site, Houston

77401

Research Site, Bellaire

80301

Research Site, Boulder

83713

Research Site, Boise

84020

Research Site, Draper

84107

Research Site, Salt Lake City

84405

Research Site, Ogden

85018

Research Site, Phoenix

85053

Research Site, Phoenix

85712

Research Site, Tucson

87102

Research Site, Albuquerque

89119

Research Site, Las Vegas

89519

Research Site, Reno

90211

Research Site, Beverly Hills

90404

Research Site, Santa Monica

91303

Research Site, Canoga Park

91360

Research Site, Thousand Oaks

91767

Research Site, Pomona

91942

Research Site, La Mesa

92103

Research Site, San Diego

92683

Research Site, Westminster

92805

Research Site, Anaheim

92840

Research Site, Garden Grove

92860

Research Site, Norco

06517

Research Site, Hamden

02111

Research Site, Boston

07728

Research Site, Freehold

Sponsors
All Listed Sponsors
lead

Biosplice Therapeutics, Inc.

INDUSTRY

NCT04385303 - A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis | Biotech Hunter | Biotech Hunter